Treating crescentic glomerulonephritis by targeting macrophages
- PMID: 36411015
- DOI: 10.1016/j.kint.2022.09.004
Treating crescentic glomerulonephritis by targeting macrophages
Abstract
Macrophage accumulation in the kidney is associated with the progression of crescentic glomerulonephritis (GN) and is mostly derived from circulating monocytes. FROUNT, a C-C motif chemokine receptor 2 (CCR2)-interacted protein, which is strongly expressed in monocytes/macrophages, enhances macrophage infiltration through CCR2-mediated chemotaxis. In this issue of the journal, Toda et al. reported that disulfiram, an inhibitor of FROUNT, attenuates GN by inhibition of the FROUNT-CCR2 interaction and macrophage migration and activation, suggesting a potential therapeutic role for crescentic GN.
Copyright © 2022 International Society of Nephrology. All rights reserved.
Comment on
-
Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis.Kidney Int. 2022 Dec;102(6):1276-1290. doi: 10.1016/j.kint.2022.07.031. Epub 2022 Aug 30. Kidney Int. 2022. PMID: 36049642
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources